Is XOMAO or ZBIO more undervalued in 2026?

CirclFi compares XOMA Royalty Corporation - Depo (XOMAO) and Zenas BioPharma, Inc. (ZBIO) using 13 institutional-grade valuation models. XOMAO has a Quality of Company score of 8.2/10 while ZBIO scores 4.7/10.

Which is a better buy — XOMAO or ZBIO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XOMAO and ZBIO valuations compare?

XOMAO at $25.36 and ZBIO at $18.56 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XOMAO vs ZBIO Valuation Comparison 2026 — Intrinsic Value Analysis

XOMAO

Biotechnology

XOMA Royalty Corporation - Depo

Quality

8.2

out of 10

Value Trap

SAFE

Price

$25.36

Last close

Models

13/13

Active

ZBIO

Biotechnology

Zenas BioPharma, Inc.

Quality

4.7

out of 10

Value Trap

LOW

Price

$18.56

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	XOMAO Fair Value	XOMAO Upside	ZBIO Fair Value	ZBIO Upside
Bayesian DCF	Intrinsic	$18.97	-25.0%	$8.02	-56.8%
Earnings Power Value	Intrinsic	$4.93	-80.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.30	-90.9%	$6.29	-66.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XOMAO vs ZBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XOMAO vs ZBIO — Which Stock Is More Undervalued?

XOMAO scores higher with a 8.2/10 quality rating vs ZBIO's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing XOMA Royalty Corporation - Depo (XOMAO) and Zenas BioPharma, Inc. (ZBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XOMAO currently trades at $25.36 with a QOC of 8.2/10, while ZBIO trades at $18.56 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).